EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudieOpen Access · CC BY 4.0

Mortality Benefit of Tranexamic Acid for Hemorrhage With Concurrent Traumatic Brain Injury: Outcomes From a Prospective Cohort Study in a High‐Trauma, Prolonged Care Setting

Julia M Dixon, Adane F Wogu, Maria D Rodriguez, Dale Barnhart, Rachel Patel, Hendrick J Lategan, George Oosthuizen, Janette Verster, Shaheem de Vries, Craig Wylie, EpiC Study Site Collaborators, Elaine Erasmus und 2 weitere

World Journal of Surgery · 2026

DOI: 10.1002/wjs.70161 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift World Journal of Surgery, 2026. Verfasst von Julia M Dixon und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency Medicine, School of Medicine, University of Colorado, Anschutz Medical Campus, Aurora, Colorado, USA. Hauptthemen laut MEDLINE: Tranexamic Acid, Brain Injuries, Traumatic, Antifibrinolytic Agents, Hemorrhage. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: United States Defense Health Agency.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Traumatic brain injury (TBI) and hemorrhage are leading causes of trauma death and disability worldwide. The concurrence of hemorrhage and brain injury carries a two‐fold increase in mortality and clinical management of patients with concurrent TBI and hemorrhage is challenging. Tranexamic acid (TXA) has been shown to reduce mortality from hemorrhage and TBI independently, however there is sparse evidence on the potential benefit of TXA in patients with both non‐head hemorrhage and TBI.

Methods

We conducted a secondary database analysis of EpiC, a multicenter, prospective cohort of trauma patients in South Africa. We compared the morbidity and mortality of patients experiencing both non‐head hemorrhage and TBI who received TXA within 3‐h post‐injury versus similarly injured patients who did not receive TXA. Inverse probability treatment weighting (IPTW) was implemented followed by a multivariable logistic regression to evaluate 7‐day mortality. Secondary outcomes included the worst 7‐day sequential organ failure assessment (SOFA) and neurologic recovery assessed by Glasgow Outcomes Score Extended (GOSE).

Results

A total of 656 patients were included in the analysis. 132 (20%) received TXA within 3 h and 544 (80%) did not. For the primary outcome of 7‐day mortality, treatment with TXA was associated with a 22% reduction in odds of death (mOR, 0.78, 95% CI, 0.62–0.98). TXA‐treated patients had significant lower odds of SOFA > 4 or death (mOR, 0.71; 95%CI, 0.53–0.95) and non‐significantly reduced odds of poor functional status at 3 months (GOSE < 7 or death) (mOR, 0.89; 95% CI, 0.68–1.18). Treatment with TXA within 2 h was associated with a 27% reduction in odds of 7‐day mortality (mOR, 0.73; 95%CI, 0.61–0.86).

Conclusions

In this study, the administration of TXA within 3 h to patients with concurrent hemorrhage and TBI was associated with a 22% reduction in mortality at 7 days. The mortality benefit was slightly larger when TXA was given within 2 h. TXA treatment was also associated with lower risk of organ failure. These results support a growing body of evidence that TXA is an effective intervention to reduce mortality and morbidity after traumatic injury.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tranexamic AcidBrain Injuries, TraumaticAntifibrinolytic AgentsHemorrhageHumansMaleFemaleProspective StudiesMiddle AgedAdultSouth AfricaTreatment Outcome

Stichwörter der Autor:innen

emergency medicineglasgow outcomes scorehemorrhagemultiple organ failuretranexamic acidtraumatraumatic brain injury

Substanzen

Tranexamic AcidAntifibrinolytic Agents

Autor:innen und Institutionen

  • Department of Emergency Medicine, School of Medicine, University of Colorado, Anschutz Medical Campus, Aurora, Colorado, USA.
  • Department of Biostatistics and Informatics, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
  • Division of Surgery, Department of Surgical Sciences, Stellenbosch University, Cape Town, South Africa.
  • Division of Forensic Medicine, Department of Pathology, Stellenbosch University, Cape Town, South Africa.
  • Collaborative for Emergency Care in Africa, Cape Town, South Africa.
  • Emergency Medical Services, Western Cape Government Health, Bellville, South Africa.

ORCID-Profile: Nee-Kofi Mould-Millman

Förderung

  • United States Defense Health Agency

Zitieren

APA

Dixon, J. M., Wogu, A. F., Rodriguez, M. D., Barnhart, D., Patel, R., Lategan, H. J., Oosthuizen, G., Verster, J., de Vries, S., Wylie, C., EpiC Study Site Collaborators, Erasmus, E., Schauer, S. G., & Mould-Millman, N. K. (2026). Mortality Benefit of Tranexamic Acid for Hemorrhage With Concurrent Traumatic Brain Injury: Outcomes From a Prospective Cohort Study in a High‐Trauma, Prolonged Care Setting. World Journal of Surgery. https://doi.org/10.1002/wjs.70161

Vancouver

Dixon JM, Wogu AF, Rodriguez MD, Barnhart D, Patel R, Lategan HJ, et al. Mortality Benefit of Tranexamic Acid for Hemorrhage With Concurrent Traumatic Brain Injury: Outcomes From a Prospective Cohort Study in a High‐Trauma, Prolonged Care Setting. World Journal of Surgery. 2026. doi:10.1002/wjs.70161

BibTeX
@article{Dixon2026,
  author = {Dixon, Julia M and Wogu, Adane F and Rodriguez, Maria D and Barnhart, Dale and Patel, Rachel and Lategan, Hendrick J and Oosthuizen, George and Verster, Janette and de Vries, Shaheem and Wylie, Craig and EpiC Study Site Collaborators, EpiC Study Site Collaborators and Erasmus, Elaine and Schauer, Steven G and Mould-Millman, Nee-Kofi},
  title = {Mortality Benefit of Tranexamic Acid for Hemorrhage With Concurrent Traumatic Brain Injury: Outcomes From a Prospective Cohort Study in a High‐Trauma, Prolonged Care Setting},
  journal = {World Journal of Surgery},
  year = {2026},
  doi = {10.1002/wjs.70161}
}
Kostenlos starten →